Rheinische Friedrich-Wilhelms-Universitaet Bonn
- Address
- lock Available on a paid plan
Cardiovascular Research
The department investigates cardiovascular diseases with a focus on improving outcomes after high‑risk cardiac surgery. One study evaluates whether an intravenous fish‑oil lipid emulsion can reduce the incidence of postoperative arrhythmias such as atrial fibrillation.
- Prevention of atrial fibrillation after cardiac procedures
- Optimization of peri‑operative lipid therapy
- Critical care strategies for intensive‑care unit patients
Rheinische Friedrich‑Wilhelms‑Universität Bonn leverages over 100 investigators to advance cardiac recovery research in collaboration with commercial partners.
Oncology and Hematology
In the field of neoplasms, the site conducts trials aimed at enhancing treatment effectiveness for rare and resistant cancers. Research includes a comparison of carboplatin versus cisplatin in patients with malignant extracranial germ‑cell tumours and a study of pembrolizumab combined with chemotherapy for platinum‑resistant ovarian carcinoma.
- Comparative efficacy of platinum‑based chemotherapy
- Integration of immunotherapy in recurrent ovarian cancer
- Biomarker‑driven approaches for germ‑cell tumor management
As an educational institution with commercial collaboration, the Bonn pediatric hematology/oncology department engages more than a hundred investigators to drive innovative cancer therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 30 therapeutic areas and 15 of 523 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 486 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 124 by active trials.
- 1AstraZeneca AB15active
lock +123 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB21trials
lock +59 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rheinische Friedrich-Wilhelms-Universitaet Bonn
lock Showing 1 of 383 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 523 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 24 | Unknown | 2018-03-06 | 2026-05-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.